| Spa47 is an oligomerization-activated type three secretion system (T3SS) ATPase from Shigella flexneri NED Jamie L. Kingsford, Heather B. Jones, Prashant Kumar, Ronald T. Toth IV ... Protein Science 25 (5), 1037-48, 2016 | 35 | 2016 |
| Characterization and protective efficacy of type III secretion proteins as a broadly protective subunit vaccine against Salmonella enterica serotypes FJ Martinez-Becerra, P Kumar, V Vishwakarma, JH Kim, O Arizmendi, ... Infection and immunity 86 (3), e00473-17, 2018 | 29 | 2018 |
| Kafirin adsorption on ion-exchange resins: isotherm and kinetic studies P Kumar, PW Lau, S Kale, S Johnson, V Pareek, R Utikar, A Lali Journal of chromatography A 1356, 105-116, 2014 | 29 | 2014 |
| Deoxycholate-Enhanced Shigella Virulence Is Regulated by a Rare π-Helix in the Type Three Secretion System Tip Protein IpaD AR Bernard, TC Jessop, P Kumar, NE Dickenson Biochemistry 56 (49), 6503-6514, 2017 | 21 | 2017 |
| Biomedical applications of lumazine synthase Y Wei, P Kumar, N Wahome, NJ Mantis, CR Middaugh Journal of Pharmaceutical Sciences 107 (9), 2283-2296, 2018 | 20 | 2018 |
| Evaluation of lumazine synthase from Bacillus anthracis as a presentation platform for polyvalent antigen display Y Wei, N Wahome, G VanSlyke, N Whitaker, P Kumar, ML Barta, ... Protein Science 26 (10), 2059-2072, 2017 | 14 | 2017 |
| Detergent isolation stabilizes and activates the Shigella type III secretion system translocator protein IpaC NED Abram Bernard, Shari Duarte, Prashant Kumar Journal of Pharmaceutical Sciences, 2016 | 13 | 2016 |
| Formulation Development of a Live Attenuated Human Rotavirus (RV3-BB) Vaccine Candidate for use in Low and Middle-Income Countries Prashant Kumar, Ravi S. Shukla, Ashaben Patel, Swathi R. Pullagurla ... Human Vaccines & Immunotherapeutics, 2021 | 11 | 2021 |
| Effect of phosphate ion on the structure of lumazine synthase, an antigen presentation system from Bacillus anthracis Y Wei, N Wahome, P Kumar, N Whitaker, WL Picking, CR Middaugh Journal of pharmaceutical sciences 107 (3), 814-823, 2018 | 11 | 2018 |
| Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication P Kumar, C Bird, D Holland, SB Joshi, DB Volkin Human Vaccines & Immunotherapeutics 18 (7), 2154100, 2022 | 9 | 2022 |
| Effect of Formulation Variables on the Stability of a Live, Rotavirus (RV3-BB) Vaccine Candidate using in vitro Gastric Digestion Models to Mimic Oral Delivery Prashant Kumar, Swathi R. Pullagurla, Ashaben Patel, Ravi S. Shukla ... Journal of Pharmaceutical Sciences 110 (2), 760-770, 2021 | 9 | 2021 |
| Biophysical Characterization of the Type III Secretion System Translocator Proteins and the Translocator Proteins Attached to Bacterium-Like Particles WDP Xiaotong Chen, Shyamal P. Choudhari, Prashant Kumar, Ronald T. Toth IV ... Journal of Pharmaceutical Sciences 104 (12), 4065-73, 2015 | 9 | 2015 |
| Modeling the long-term 2-8° C stability profiles of a live, rotavirus vaccine candidate (RV3-BB) in various liquid formulations via extrapolations of real-time and accelerated … SR Pullagurla, P Kumar, O Ogun, OS Kumru, A Hamidi, F Hoeksema, ... Biologicals 75, 21-28, 2022 | 6 | 2022 |
| Vaccination with mouse dendritic cells loaded with an IpaD-IpaB fusion provides protection against shigellosis O Arizmendi, P Kumar, Q Zheng, JP Stewart, WD Picking, W Picking, ... Frontiers in Immunology 10, 192, 2019 | 6 | 2019 |
| Concordance of in vitro and in vivo measures of non-replicating rotavirus vaccine potency Dave McAdams, Marcus Estrada, David Holland, Jasneet Singh, Nishant Sawant ... Vaccine, 2022 | 5 | 2022 |
| Developing a manufacturing process to deliver a cost effective and stable liquid human rotavirus vaccine A Hamidi, F Hoeksema, P Velthof, A Lemckert, G Gillissen, A Luitjens, ... Vaccine 39 (15), 2048-2059, 2021 | 5 | 2021 |
| Co-treatment with sulforaphane–zein microparticles enhances the chemopreventive potential of zinc in a 1, 2-dimethylhydrazine induced colon carcinogenesis rat model V Sridhar, S Narnaware, P Kumar, SB Kale, AS Majumdar RSC advances 6 (41), 34233-34244, 2016 | 4 | 2016 |
| Multi-dose formulation development for a quadrivalent human papillomavirus virus-like particle-based vaccine: part I-screening of preservative combinations K Jerajani, Y Wan, OS Kumru, SR Pullagurla, P Kumar, N Sharma, ... Journal of Pharmaceutical Sciences 112 (2), 446-457, 2023 | 3 | 2023 |
| Correlating physicochemical and biological properties to define critical quality attributes of a recombinant AAV vaccine candidate Prashant Kumar, Michael Wang, Ozan S. Kumru, John Hickey, Julio Sanmiguel ... Molecular Therapy - Methods & Clinical Development, 2023 | 1* | 2023 |
| Novel Approaches for Overcoming Biological Barriers V Agrahari, P Kumar Pharmaceutics 14 (9), 1851, 2022 | 1 | 2022 |
Yangjie WeiAmgenamgen.com의 이메일 확인됨
